Immunotoxin

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, AstraZeneca, Merck, Cancer, Doctor of Philosophy, Spacecraft, B7-H4, Antibody, Johnson & Johnson, Immunotoxin, CSO, MedImmune

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.

Key Points: 
  • BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.
  • As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4.
  • “We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug conjugates,” said Solomon Langermann, PhD, NextCure’s chief scientific officer.
  • “Rakesh is a world authority on ADCs and has an incredible record of researching and developing them.

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

Retrieved on: 
Monday, August 7, 2023
American literature, Drug development, Faculty of Tropical Medicine, Mahidol University, Therapy, Nilotinib, Decoy, Business administration, Hospital, Novartis, Patient, Columbia Business School, Brown University, Immunotoxin, Pharmaceutical industry

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces the appointment of Roger Waltzman, M.D.

Key Points: 
  • NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces the appointment of Roger Waltzman, M.D.
  • as its Chief Medical Officer, effective August 7, 2023.
  • Jeffrey Meckler, Indaptus’ CEO commented, “Roger’s deep experience in drug development, particularly in the field of immuno-oncology, and his time as an officer at development and clinical-stage companies makes him an ideal candidate to assume the position of chief medical officer at Indaptus.
  • Prior, he served in the c-suite as Chief Medical Officer at Rgenix, Inc. (now Inspirna, Inc) and as Chief Scientific Officer at Jaguar Health.

Pinetree Therapeutics Announces Two Appointments to Strengthen its Scientific Leadership

Retrieved on: 
Wednesday, May 31, 2023
Therapy, Regeneron Pharmaceuticals, Seagen, Biotechnology, MedImmune, Cancer, United States Air Force Scientific Advisory Board, Janssen, TPD, Research, Bristol Myers Squibb, Doctor of Philosophy, Rutgers University, Pinetree, Selective estrogen receptor degrader, DRS, Novartis, Patient, Molecular Partners, Engineering, Boehringer Ingelheim, Immunotoxin, BMS, IND, Disease, Pharmaceutical industry, Vaccine, Bayer, Merck

CAMBRIDGE, Mass., May 31, 2023 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree" or the "Company"), an emerging and award winning biotechnology company pioneering next generation targeted protein degraders (TPD) to overcome the shortcomings of existing therapies, today announced the addition of Pamela A. Trail, PhD, to its Scientific Advisory Board as well as the appointment of John Majercak, PhD, as Chief Technology Officer.

Key Points: 
  • Trail, PhD, to its Scientific Advisory Board as well as the appointment of John Majercak, PhD, as Chief Technology Officer.
  • "I am pleased to join the Scientific Advisory Board at Pinetree Therapeutics at this exciting time", said Dr.
  • "The novel platforms at Pinetree Therapeutics provide unique opportunities to develop therapeutics for treatment of diseases with high unmet medical need."
  • Dr. Majercak added, "I am thrilled to join Pinetree Therapeutics to help bring new treatment options to cancer patients.

Novel Antibody Therapies Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Health, Pharmaceutical, Growth, Lymphoma, Administration, Hairy cell leukemia, Antibody, Membrane protein, Combination therapy, Cell, Acute myeloid leukemia, Precursor cell, Partnership, Prostate, Graft-versus-host disease, Prostate cancer, Protein, T-cell lymphoma, Urinary bladder, Soft-tissue sarcoma, Bladder cancer, Research, Therapy, Immunotoxin, Mycosis fungoides, Publication, Type, B-cell lymphoma, Hodgkin lymphoma, Vaccine, Risk management, Pharmaceutical industry

The "Novel Antibody Therapies Market: Distribution by Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Novel Antibody Therapies Market: Distribution by Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • The 'Novel Antibody Therapies Market, 2022-2035' report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the novel antibody therapies in the treatment of various diseases.
  • What are the different initiatives undertaken by big pharma players for the development of novel antibody therapies in the recent past?
  • How is the current and future market opportunity, related to novel antibody therapies likely to be distributed across key market segments?

Global Acute Myeloid Leukemia Therapeutics Market Report (2022 to 2027) - Improved Immunotoxins, Alkylating Agents, Monoclonal Antibodies and Multidrug-Resistant Modulators is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, October 21, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Adoption, Globe, Acute myeloid leukemia, Leukemia, Weight loss, Therapy, Fatigue, Transplant, Prevalence, Growth, AML, Nosebleed, Research, Bone marrow, R, Immunotoxin, Immune system, Disorder, Industry, Awareness, Skin, White blood cell, COVID-19, Pharmaceutical industry, Vaccine

The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market.

Key Points: 
  • The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market.
  • What has been the impact of COVID-19 on the global acute myeloid leukemia therapeutics market?
  • What is the structure of the global acute myeloid leukemia therapeutics market and who are the key players?
  • The publisher provides an analysis of the key trends in each sub-segment of the global acute myeloid leukemia therapeutics market report, along with forecasts at the global, regional and country level from 2022-2027.

Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to Advisory Board

Retrieved on: 
Wednesday, September 7, 2022
People, MedImmune, AstraZeneca, CEO, Cancer, Antibody-drug conjugate, DABT, Asthma, Pharmaceutical industry, CSO, Antibody, Control, Biotechnology, Therapy, Atopic dermatitis, Advisory board, ADC, Merck, Johnson & Johnson, Immunotoxin, Drug development, Patient, Fine chemical, Vaccine

"I'm delighted to work with the team at Biosion to bolster their mission to deliver breakthrough therapeutics to patients globally."

Key Points: 
  • "I'm delighted to work with the team at Biosion to bolster their mission to deliver breakthrough therapeutics to patients globally."
  • "Biosion's SynTracer internalization platform is uniquely positioned to deliver fit-for-purpose monoclonal antibodies for ADC candidates, a next generation approach to targeting cancer."
  • Dr. Dixit was honored in 2020 by the World ADC Forum with its most prestigious award of Long Standing Contributor to ADCs.
  • Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in phase-II for severe asthma and phase-I for atopic dermatitis.

Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. to Join Leadership Team

Retrieved on: 
Monday, January 10, 2022
Safety, Lucknow, Risk, SAN, Gene, Neoplasm, Central Drug Research Institute, Security (finance), List of life sciences, Cancer, Clinical professor, Patient, Research, Mayo Clinic, NASDAQ, U.S. Securities and Exchange Commission, Health, Employment, Annual report, Center, Forward-looking statement, TIL, Translational medicine, Immunotoxin, Food, PBL, Food and Drug Administration, Private Securities Litigation Reform Act, Company, Center for Biologics Evaluation and Research, Lymphocyte, Lymphatic system, Cervical cancer, University, PSLRA, FDA, COVID-19, National Cancer Institute, Perception, GLOBE, Medicine, Division, Population, Pharmaceutical industry, Iovance Biotherapeutics, Tissue, Iovance Biotherapeutics

Dr. Puri will begin his employment with the Company toward the end of the first quarter of 2022.

Key Points: 
  • Dr. Puri will begin his employment with the Company toward the end of the first quarter of 2022.
  • He is also a Chief of Tumor Vaccines and Biotechnology Branch within DCGT.
  • Dr. Puri has experience with the evaluation and regulation of advanced therapies including cell and gene therapy, cancer vaccines, and cellular immunotherapy.
  • Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers.

Global Acute Myeloid Leukemia Therapeutics Market Report 2021: Industry Trends, Shares, and Growth Opportunities to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 8, 2021
Health, General Health, Disorder, Prevalence, Awareness, Leukemia, R, Research, Globe, CAGR, Therapy, AML, Immunotoxin, Adoption, Vaccine

The "Acute Myeloid Leukemia Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Myeloid Leukemia Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global acute myeloid leukemia therapeutics market grew at a CAGR of around 7% during 2015-2020.
  • The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market.
  • The report provides an analysis of the key trends in each sub-segment of the global acute myeloid leukemia therapeutics market, along with forecasts at the global, regional and country level from 2021-2026.

Global Acute Myeloid Leukemia (AML) Therapeutics Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 6, 2021
Health, General Health, Acute myeloid leukemia, Cytarabine, Ageing, Pharmacology, Safety, Medication, Nausea, Population, FMS, CAGR, AML, Prevalence, Benzene, Symptoms of COVID-19, Molecular biology, COVID-19, Immunotoxin, Radiation exposure, Research, Investment, Therapy, Growth, Pharmaceutical industry, Pet

The "Acute Myeloid Leukemia (AML) Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Myeloid Leukemia (AML) Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • This segment currently accounts for a 18.2% share of the global Acute Myeloid Leukemia (AML) Therapeutics market.
  • These R&D endeavors are also attributed to limitations associated with existing therapies available on the market for acute myeloid leukemia.
  • The U.S. Market is Estimated at $194.4 Million in 2021, While China is Forecast to Reach $85.7 Million by 2026
    The Acute Myeloid Leukemia (AML) Therapeutics market in the U.S. is estimated at US$194.4 Million in the year 2021.

Considerations for Immunology and Immunotoxicology Endpoints in Early Drug Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, April 6, 2021
Immunotoxin, Immunotoxicology

TORONTO, Ontario, April 6, 2021 /PRNewswire-PRWeb/ -- There are many considerations for Immunology and Immunotoxicology (I&I) assessments that are needed during the early phase of drug development.

Key Points: 
  • TORONTO, Ontario, April 6, 2021 /PRNewswire-PRWeb/ -- There are many considerations for Immunology and Immunotoxicology (I&I) assessments that are needed during the early phase of drug development.
  • For more information, or to register for this event, visit Considerations for Immunology and Immunotoxicology Endpoints in Early Drug Development .
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.